FindTrial
Sign In

Clinical study for infusing convalescent plasma to treat patients with new coronavirus pneumonia (COVID-19)

Clinical study for infusing convalescent plasma to treat patients with new coronavirus pneumonia (COVID-19)

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000030039
Enrollment
Unknown
Registered
2020-02-21
Start date
2020-05-31
Completion date
Unknown
Last updated
2020-02-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Novel Coronavirus Pneumonia (COVID-19)

Interventions

Experimental group:conventional therapy with Infusion of convalescent plasma: 200-500ml, two infusions are recommended
control group:conventional therapy

Sponsors

Affiliated Hospital of Xuzhou Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. The diagnosis conforms to the diagnostic criteria of "pneumonia diagnosis and treatment program for new coronavirus infection (trial version 5)"; 2. Clinical classification is normal,severe or critical; 3. Subject aged >=18 years old; 4. The patient or his/her legal guardian will participate voluntarily and sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Highly allergic constitution or history of severe allergy, especially plasma allergy; 2. The doctor believes that there are other reasons not to include the healer.

Design outcomes

Primary

MeasureTime frame
SARS-CoV-2 DNA;SARS-CoV-2 antibody levels;thoracic spiral CT;—

Secondary

MeasureTime frame
CRP;IL-6;LDH;CK;liver function;runal function;respiratory rate;SiO2;—

Countries

China

Contacts

Public ContactXuebing Yan

Affiliated Hospital of Xuzhou Medical University

yxbxuzhou@126.com+86 15205215685

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026